JP2021521138A5 - - Google Patents

Info

Publication number
JP2021521138A5
JP2021521138A5 JP2020555218A JP2020555218A JP2021521138A5 JP 2021521138 A5 JP2021521138 A5 JP 2021521138A5 JP 2020555218 A JP2020555218 A JP 2020555218A JP 2020555218 A JP2020555218 A JP 2020555218A JP 2021521138 A5 JP2021521138 A5 JP 2021521138A5
Authority
JP
Japan
Prior art keywords
methyl
tetrahydro
oxy
sulfonyl
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020555218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/085001 external-priority patent/WO2019210828A1/en
Publication of JP2021521138A publication Critical patent/JP2021521138A/ja
Publication of JP2021521138A5 publication Critical patent/JP2021521138A5/ja
Priority to JP2024094048A priority Critical patent/JP7540113B1/ja
Priority to JP2024135320A priority patent/JP7688210B2/ja
Priority to JP2025085498A priority patent/JP2025119001A/ja
Withdrawn legal-status Critical Current

Links

JP2020555218A 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤 Withdrawn JP2021521138A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024094048A JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/085217 2018-04-29
CN2018085217 2018-04-29
CNPCT/CN2018/107134 2018-09-21
CN2018107134 2018-09-21
PCT/CN2019/085001 WO2019210828A1 (en) 2018-04-29 2019-04-29 Bcl-2 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094048A Division JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤

Publications (2)

Publication Number Publication Date
JP2021521138A JP2021521138A (ja) 2021-08-26
JP2021521138A5 true JP2021521138A5 (enExample) 2022-04-22

Family

ID=68386968

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020555218A Withdrawn JP2021521138A (ja) 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Country Status (22)

Country Link
US (3) US11420968B2 (enExample)
EP (2) EP4545515A1 (enExample)
JP (4) JP2021521138A (enExample)
KR (1) KR102738032B1 (enExample)
CN (3) CN112437772B (enExample)
AU (1) AU2019264475C1 (enExample)
BR (1) BR112020022092A2 (enExample)
CA (1) CA3098348A1 (enExample)
DK (1) DK3788042T3 (enExample)
ES (1) ES3018793T3 (enExample)
FI (1) FI3788042T3 (enExample)
HR (1) HRP20250392T1 (enExample)
HU (1) HUE071493T2 (enExample)
IL (1) IL278366B2 (enExample)
LT (1) LT3788042T (enExample)
MX (2) MX2020011495A (enExample)
PL (1) PL3788042T3 (enExample)
PT (1) PT3788042T (enExample)
SG (1) SG11202009933WA (enExample)
SI (1) SI3788042T1 (enExample)
TW (1) TWI855062B (enExample)
WO (1) WO2019210828A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) * 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
KR20220100992A (ko) 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
BR112022012283A2 (pt) 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
MX2022014007A (es) * 2020-05-08 2023-02-09 Fochon Pharmaceuticals Ltd Compuestos como inhibidores de bcl-2.
WO2022089463A1 (zh) * 2020-10-28 2022-05-05 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
BR112023017371A2 (pt) * 2021-03-19 2023-10-03 Eil Therapeutics Inc Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2
US20240239792A1 (en) * 2021-04-13 2024-07-18 Appicine Therapeutics (Hk) Limited Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
MX2023014275A (es) * 2021-06-02 2024-03-06 Beigene Switzerland Gmbh Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2.
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
MX2024002465A (es) * 2021-08-31 2024-04-29 Beigene Ltd Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos.
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
JP2024540590A (ja) * 2021-11-20 2024-10-31 フォチョン・バイオサイエンシーズ・リミテッド Ｂｃｌ－２阻害剤としての化合物
JP7765790B2 (ja) * 2021-12-06 2025-11-07 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用
TW202400163A (zh) 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
KR20250079128A (ko) * 2022-07-21 2025-06-04 베이진 스위찰랜드 게엠베하 Bcl-2 저해제를 사용한 다발성 골수종의 치료 방법
WO2024140678A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. A ketal protected intermediate for sonrotoclax and preparation method thereof
WO2024140692A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. Salts and solid forms of sonrotoclax intermediate
WO2024140690A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. Intermediates of sonrotoclax and the method of preparing the same
TW202604488A (zh) 2024-06-26 2026-02-01 瑞士商百濟神州Ｉ有限責任公司 包含索托克拉固體分散體之醫藥調配物及其製備方法
WO2026019442A1 (en) * 2024-07-14 2026-01-22 Eil Therapeutics, Inc. Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
BRPI0514504A (pt) 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
EP1888543B1 (en) 2005-05-24 2012-08-01 Abbott Laboratories Apoptosis promoters
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
US8501992B2 (en) 2008-06-09 2013-08-06 Bristol-Myers Squibb Company Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
NZ614305A (en) 2008-12-05 2015-03-27 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN102307862A (zh) 2008-12-08 2012-01-04 贝林格尔.英格海姆国际有限公司 用于治疗癌症的化合物
NZ616828A (en) 2009-01-19 2015-03-27 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR112012005343A2 (pt) 2009-09-10 2016-03-22 Novartis Ag sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer
AU2011229862B2 (en) 2010-03-25 2014-07-24 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
CN103732589B (zh) 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
WO2013053045A1 (en) 2011-10-12 2013-04-18 Beta Pharma Canada Inc. Heterocyclic molecules as apoptosis inducers
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
EP2945940B1 (en) 2013-01-16 2020-07-15 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN109641897B (zh) 2016-09-01 2021-12-07 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
CN106749233B (zh) 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Similar Documents

Publication Publication Date Title
IL278366B2 (en) BCL-2 inhibitors
JP2022504936A5 (enExample)
GB2609879A (en) Antagonists of the adenosine A2a receptor
JP2017531672A5 (enExample)
CA2623982A1 (en) Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
JP2024515545A5 (enExample)
RU2013126657A (ru) Ингибиторы nampt и rock
RU2020129785A (ru) Фармацевтические производные 6,5-гетеробициклического кольца
RU2018126774A (ru) Ингибиторы менин-mll взаимодействия
HRP20150269T1 (hr) Inhibitori beta-laktamaze
JP2011511003A5 (enExample)
JP2017505327A5 (enExample)
CA2393809A1 (en) Heterocyclic dihydropyrimidines as potassium channel inhibitors
JP2009516743A5 (enExample)
RU2010116759A (ru) Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
JP2018530557A5 (enExample)
JP2023525762A5 (enExample)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2017524007A5 (enExample)
RU2017117248A (ru) Этил-n-boc-пиперидинил-пиразоло-пиридоны в качестве ингибиторов янус-киназы
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
RU2004121166A (ru) 2-аминобензотиазолилмочевины в качестве модуляторов аденозина
JP2015526395A5 (enExample)
JP2015513552A5 (enExample)
JP2015537010A5 (enExample)